VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE)
CUSIP: 92941V308
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 18,514,484
- Total 13F shares
- 8,048,768
- Share change
- +938,479
- Total reported value
- $13,279,291
- Price per share
- $1.65
- Number of holders
- 44
- Value change
- +$1,503,898
- Number of buys
- 22
- Number of sells
- 19
Quarterly Holders Quick Answers
What is CUSIP 92941V308?
CUSIP 92941V308 identifies VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 92941V308:
Top shareholders of VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,935,057
|
$11,251,930 | — | 16 Aug 2021 | |
| AI Biotechnology LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,116,585
|
$2,545,814 | — | 01 Nov 2023 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
7.5%
|
1,394,336
|
$2,370,371 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
5.9%
|
1,100,329
|
$1,738,520 | — | 31 Mar 2025 | |
| ACORN CAPITAL ADVISORS, LLC |
13F
|
Company |
4.2%
|
785,938
|
$1,241,782 | — | 31 Mar 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
3.4%
|
636,103
|
$1,005,043 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.6%
|
475,650
|
$751,527 | — | 31 Mar 2025 | |
| Exome Asset Management LLC |
13F
|
Company |
2.5%
|
462,801
|
$731,225 | — | 31 Mar 2025 | |
| Palo Alto Investors LP |
13F
|
Company |
2.4%
|
445,434
|
$703,786 | — | 31 Mar 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.9%
|
344,134
|
$543,732 | — | 31 Mar 2025 | |
| Patient Square Capital LP |
13F
|
Company |
1.4%
|
257,033
|
$406,112 | — | 31 Mar 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
1.2%
|
217,978
|
$344,405 | — | 31 Mar 2025 | |
| Andrew Saik |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
116,468
|
$265,547 | — | 28 May 2021 | |
| Matthew T. Wiley |
3/4/5
|
Chief Commercial Officer |
—
class O/S missing
|
109,246
|
$249,081 | — | 30 Jun 2021 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.76%
|
141,502
|
$223,573 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.72%
|
133,490
|
$210,928 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.62%
|
115,143
|
$181,926 | — | 31 Mar 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.46%
|
84,978
|
$134,264 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.45%
|
82,579
|
$130,474 | — | 31 Mar 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.38%
|
70,419
|
$111,262 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.31%
|
57,762
|
$91,264 | — | 31 Mar 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.28%
|
51,958
|
$82,094 | — | 31 Mar 2025 | |
| STALEY CAPITAL ADVISERS INC |
13F
|
Company |
—
class O/S missing
|
51,472
|
$81,326 | — | 31 Mar 2025 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.25%
|
45,557
|
$71,980 | — | 31 Mar 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.18%
|
33,052
|
$52,222 | — | 31 Mar 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.14%
|
26,242
|
$41,000 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.13%
|
23,971
|
$37,874 | — | 31 Mar 2025 | |
| Virtu Financial LLC |
13F
|
Company |
0.11%
|
19,574
|
$31,000 | — | 31 Mar 2025 | |
| COMMONWEALTH EQUITY SERVICES, LLC |
13F
|
Company |
0.1%
|
18,298
|
$29,000 | — | 31 Mar 2025 | |
| Shay Capital LLC |
13F
|
Company |
0.1%
|
18,015
|
$28,464 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.09%
|
17,163
|
$27,118 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.09%
|
15,765
|
$24,909 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.07%
|
12,811
|
$20,241 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.04%
|
7,576
|
$11,970 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.03%
|
5,981
|
$9,450 | — | 31 Mar 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.02%
|
4,296
|
$6,788 | — | 31 Mar 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.01%
|
2,440
|
$4,000 | — | 31 Mar 2025 | |
| MB, LEVIS & ASSOCIATES, LLC |
13F
|
Company |
0.01%
|
1,041
|
$1,645 | — | 31 Mar 2025 | |
| CWM, LLC |
13F
|
Company |
0%
|
500
|
$1,000 | — | 31 Mar 2025 | |
| Centerpoint Advisors, LLC |
13F
|
Company |
0%
|
350
|
$1,000 | — | 31 Mar 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
65
|
$103 | — | 31 Mar 2025 | |
| Truvestments Capital LLC |
13F
|
Company |
0%
|
25
|
$40 | — | 31 Mar 2025 | |
| Rex Bright |
3/4/5
|
Director |
—
class O/S missing
|
20,500
|
— | — | 19 Jul 2021 | |
| Anthony D. Bruno |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 12 Dec 2024 | |
| Christine Borowski |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 12 Dec 2024 |
Institutional Holders of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) as of Q2 2025
As of 30 Jun 2025,
VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) was held by
44 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,048,768 shares.
The largest 10 holders included
Cormorant Asset Management, LP, CITADEL ADVISORS LLC, ACORN CAPITAL ADVISORS, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., DAFNA Capital Management LLC, KENNEDY CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, Palo Alto Investors LP, Patient Square Capital LP, and Ikarian Capital, LLC.
This page lists
44
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
36
Q2 2025 holders
44
Holder diff
8
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.